Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5.

Cancer Gene Therapy
Zhiheng ChengLin Fu

Abstract

The mutational spectrum and molecular characteristics of acute myelomonocytic lineage leukemia, namely acute myeloid leukemia (AML) French-American-British (FAB) subtypes M4 and M5, are largely unknown. In order to explore the mutational spectrum and prognostic factors of FAB-M4 and -M5, next-generation sequencing (NGS) was performed to screen for mutated genes and fusion genes relevant to the pathogenesis of AML. Of the 63 patients enrolled in the study, 60% had more than three mutated genes. NPM1 had the highest mutation frequency, followed by DNMT3A, FLT3, NRAS, RUNX1, and TET2. Univariate analysis suggested that age ≥60 years was an independent factor for both poor event-free survival (EFS) and overall survival (OS, P = 0.009, 0.002, respectively), MYH11-CBFβ was associated with better EFS and OS (P = 0.029, 0.016, respectively). However, multivariate analysis was not able to identify any independent risk factor for survival in the cohort of FAB-M4 and -M5 patients, including peripheral white blood cell count, bone marrow blast percentage, MYH11-CBFβ, FLT3-ITD, mutations in NPM1 and DNMT3A, and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our study provided new insight into the mutational spectrum and mol...Continue Reading

References

Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Mar 19, 2011·Leukemia·M J WalterT A Graubert
Sep 29, 2011·Seminars in Oncology·Mario CazzolaLuca Malcovati
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Dec 18, 2012·British Journal of Haematology·Yishai Ofran, Jacob M Rowe
Jan 9, 2013·British Journal of Haematology·Alexander KohlmannTorsten Haferlach
Jan 30, 2013·International Journal of Hematology·Tomoki Naoe, Hitoshi Kiyoi
Mar 26, 2013·American Journal of Hematology·Elihu H Estey
Apr 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Levi A Garraway
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Dec 10, 2013·Hematology·Richard F Schlenk, Hartmut Döhner
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Aug 21, 2016·Mutation Research. Reviews in Mutation Research·Bani Bandana Ganguly, N N Kadam

❮ Previous
Next ❯

Citations

Nov 23, 2019·Journal of Cellular and Molecular Medicine·Zhiheng ChengLin Fu
Dec 22, 2020·ACS Pharmacology & Translational Science·Alessandra MessikommerNathan W Luedtke

❮ Previous
Next ❯

Software Mentioned

Mutational Significance in Cancer ( MuSiC )
Picard
SPSS
Maq
BWA
GraphPad Prism

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.